Morgan Stanley Candel Therapeutics, Inc. Transaction History

Morgan Stanley

$1.59 Trillion
Q3 2025

A detailed history of Morgan Stanley transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 75,941 shares of CADL stock, worth $350,088. This represents 0.0% of its overall portfolio holdings.

Number of Shares

75,941

Previous 113,722 33.22%

Holding current value

$350,088

Previous $575,000 32.17%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$4.79 - $7.0 $180,970 - $264,467	-37,781 Reduced 33.22%	75,941 $390,000
Q2 2025 Aug 15, 2025	BUY	$4.39 - $6.04 $224,969 - $309,525	51,246 Added 82.03%	113,722 $575,000
Q1 2025 May 15, 2025	SELL	$5.65 - $12.21 $72,314 - $156,275	-12,799 Reduced 17.0%	62,476 $352,000
Q4 2024 Feb 14, 2025	BUY	$3.96 - $9.96 $42,934 - $107,986	10,842 Added 16.83%	75,275 $653,000
Q3 2024 May 14, 2025	BUY	$5.02 - $7.76 $225,774 - $349,006	44,975 Added 231.14%	64,433 $446,000

Q3 2024 Nov 14, 2024	BUY	$5.02 - $7.76 $225,774 - $349,006	44,975 Added 231.14%	64,433 $446,000
Q2 2024 May 14, 2025	SELL	$1.68 - $14.0 $93,772 - $781,438	-55,817 Reduced 74.15%	19,458 $120,000
Q2 2024 Aug 14, 2024	BUY	$1.68 - $14.0 $32,689 - $272,412	19,458 New	19,458 $120,000
Q4 2022 Feb 14, 2023	SELL	$1.48 - $3.2 $7,678 - $16,601	-5,188 Reduced 98.26%	92 $0
Q3 2022 Nov 14, 2022	BUY	$3.05 - $4.08 $2,009 - $2,688	659 Added 14.26%	5,280 $17,000
Q2 2022 Oct 27, 2022	SELL	$3.13 - $5.56 $93 - $166	-30 Reduced 0.65%	4,621 $15,000
Q2 2022 Aug 15, 2022	SELL	$3.13 - $5.56 $93 - $166	-30 Reduced 0.65%	4,621 $15,000
Q1 2022 Oct 27, 2022	BUY	$3.66 - $8.0 $109 - $240	30 Added 0.65%	4,651 $24,000
Q1 2022 May 13, 2022	SELL	$3.66 - $8.0 $259 - $568	-71 Reduced 1.5%	4,651 $24,000
Q4 2021 Feb 14, 2022	BUY	$6.34 - $11.9 $29,937 - $56,191	4,722 New	4,722 $36,000

Others Institutions Holding CADL

# of Institutions

Shares Held

14.9M

Call Options Held

313K

Put Options Held

127K

View Full List

About Candel Therapeutics, Inc.

Ticker CADL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,891,900
Market Cap $133M
Description
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...

More about CADL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account